FREZENT Biological Solutions

FREZENT is a preclinical-stage oncology therapeutics company based in New York. We are developing bispecific antibodies and antibody-drug conjugates aimed at targeting dormant cancer cells that may lead to cancer recurrence. Dormant cancer cells are small residual portions of a tumor that were not completely eliminated by treatment. These cells can remain undetectable in the body for a period of time, but eventually, they can transform back into fast-growing tumors. FREZENT is working on a novel cancer treatment to block the reactivation of dormant cancer cells. To achieve this, we are developing therapeutics that neutralize the metabolic factors supplied by the tumor microenvironment, which support dormant cancer cells. In their dormant state, cancer cells rely on these external supplies, and blocking them will effectively starve the cancer cells and induce cell death. Join us in our mission to ensure a future where long-lasting remission is a reality for all cancer patients.